Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33525631 | 0.77 | POLB (0.33) | MAPT | |
| SCHEMBL33525625 | 0.76 | LMNA (0.31) | RXFP1LMNATP53MAPT | |
| SCHEMBL33525688 | 0.74 | — | — | |
| SCHEMBL33525708 | 0.74 | POLB (0.33) | MAPT | |
| SCHEMBL33525544 | 0.73 | LMNA (0.32) | RXFP1LMNATP53MAPT | |
| SCHEMBL33525612 | 0.72 | — | — | |
| SCHEMBL33526346 | 0.69 | — | — | |
| SCHEMBL33525847 | 0.69 | LMNA (0.32) | RXFP1LMNATP53MAPT | |
| SCHEMBL34461996 | 0.68 | — | — | |
| SCHEMBL33525573 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | ELI LILLY AND COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | KRAS, NRAS, HRAS | PDE7A 3839/4885RXFP1 2542/4885LMNA 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.